AstraZeneca's Tezspire Gets EU Approval for Severe Asthma Treatment
21 Septiembre 2022 - 1:50AM
Noticias Dow Jones
By Michael Susin
AstraZeneca PLC said Wednesday that its tezepelumab treatment
Tezspire has been approved in the European Union for patients with
severe asthma.
The Anglo-Swedish pharmaceutical giant said that Tezspire will
be used as an add-on maintenance treatment in patients who are
inadequately controlled with high dose of inhaled corticosteroids
and other products.
The treatment has been previously approved in the U.S. and other
countries and regulatory reviews are ongoing in additional
countries, the company said.
"Tezspire is now the first and only biologic approved in Europe
for patients with severe asthma with no phenotype or biomarker
limitation and we look forward to bringing this important medicine
to patients as quickly as possible," Mene Pangalos, AstraZeneca's
executive vice president of biopharmaceuticals research and
development, said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 21, 2022 02:35 ET (06:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
